Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $20.00.

Several equities research analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Altimmune in a report on Thursday. Evercore ISI raised Altimmune to a "strong-buy" rating in a report on Friday, August 9th. B. Riley reaffirmed a "buy" rating and issued a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. Finally, UBS Group started coverage on Altimmune in a research note on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price objective on the stock.

Altimmune Trading Down 6.0 %

Altimmune stock traded down $0.46 during mid-day trading on Monday, reaching $7.15. The company's stock had a trading volume of 4,476,008 shares, compared to its average volume of 3,874,781. The business has a 50 day moving average price of $7.02 and a 200-day moving average price of $6.91. The firm has a market cap of $508.54 million, a price-to-earnings ratio of -4.61 and a beta of 0.09. Altimmune has a twelve month low of $2.41 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the previous year, the business posted ($0.39) earnings per share. On average, equities analysts expect that Altimmune will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of large investors have recently modified their holdings of ALT. Geode Capital Management LLC lifted its holdings in Altimmune by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company's stock worth $10,244,000 after buying an additional 74,194 shares during the period. Bellevue Group AG boosted its stake in shares of Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company's stock worth $5,303,000 after buying an additional 263,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock worth $3,791,000 after buying an additional 335,444 shares during the last quarter. Knoll Capital Management LLC lifted its stake in Altimmune by 183.6% in the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company's stock valued at $5,774,000 after purchasing an additional 367,219 shares during the last quarter. Finally, Farallon Capital Management LLC raised its holdings in Altimmune by 1,282.4% during the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company's stock valued at $4,785,000 after acquiring an additional 436,000 shares during the period. Institutional investors and hedge funds own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.